Trial · NCT02504372
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Disease-Free Survival (DFS) | Pembrolizumab | 53.8 | 95% Confidence Interval 46.2 to 67.0 | Months | |
| Disease-Free Survival (DFS) | Placebo | 43.0 | 95% Confidence Interval 35.0 to 51.6 | Months | |
| DFS in Programmed Death Ligand-1 (PDL-1) Strong Positive Participants With Tumor Proportion Score (TPS) ≥50% | Pembrolizumab | 67.0 | 95% Confidence Interval 47.8 to NA | Months | |
| DFS in Programmed Death Ligand-1 (PDL-1) Strong Positive Participants With Tumor Proportion Score (TPS) ≥50% | Placebo | 47.6 | 95% Confidence Interval 36.4 to NA | Months | |
| DFS in PDL-1 Strong Positive Participants With TPS ≥1% | Pembrolizumab | 58.7 | 95% Confidence Interval 46.2 to 76.7 | Months | |
| DFS in PDL-1 Strong Positive Participants With TPS ≥1% | Placebo | 42.8 | 95% Confidence Interval 35.0 to 57.8 | Months | |
| Number of Participants Who Experienced an Adverse Event (AE) | Pembrolizumab | 556 | Participants | ||
| Number of Participants Who Experienced an Adverse Event (AE) | Placebo | 529 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | Pembrolizumab | 116 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | Placebo | 34 | Participants | ||
| DFS at 68 Months | Pembrolizumab | 53.6 | 95% Confidence Interval 39.2 to NA | Months | |
| DFS at 68 Months | Placebo | 42.0 | 95% Confidence Interval 31.3 to NA | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02504372/results